All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
At the American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, on Tuesday 4th April, a poster session titled “Tumor Evolution and Heterogeneity 2” took place.
One of the posters on display (3939 / 6) was titled “Evolution and drug resistance of primary and relapse tumors in Diffuse Large B-Cell Lymphoma” by Rainer Lehtonen from the University of Helsinki, Helsinki, Finland, and colleagues.
This group carried out integrated multi-omics (whole genome, transcriptome, and methylome) analyses complemented with mathematical modelling of pared primary and relapsed DLBCL tumors. They aimed to provide a comprehensive view of tumor evolution, drug resistance, and disease heterogeneity. In total, 23 fresh frozen and 28 paraffin embedded samples from 24 advanced disease patients with at least one relapse were included.
The group concluded the poster by hypothesizing two evolutionary models, which take into account disease subtype, PFS and OS, treatment response at diagnosis and relapse, and molecular features:
References
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?